Eylea Biosimilar Race Hots Up As Formycon Launches Phase III Trials

Formycon Collaborating With Partner Bioeq

 
• By Dean Rudge

Formycon has pushed its second ophthalmology biosimilar candidate into Phase III trials, the German firm’s Eylea (aflibercept) biosimilar, FYB203, which has been licensed to Bioeq. Multiple firms are now circling Eylea, ahead of a projected US market formation in 2023.

Female eye with long eyelashes close up. Closeup shot of female gray - blue colour eye with day makeup. Beauty female eye with curl long eyelashes
Eylea represents one of the largest biological opportunities in the world. • Source: Shutterstock

More from Products

More from Generics Bulletin